A study of CTA313 for people with autoimmune diseases
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests an investigational drug called CTA313 in people with certain autoimmune diseases that haven't improved with other treatments. It aims to see if the drug can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with one of these: systemic lupus erythematosus (SLE), primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (SPMS), or autoimmune encephalitis (AIE).
- For lupus: you have already tried at least two different immune-suppressing drugs and one biologic agent, and it didn't work well enough.
- For multiple sclerosis: you have PPMS or non-active SPMS.
- Your organs (like kidneys, liver, and heart) are working well enough as shown by lab tests.
- You have not had certain heart problems (like heart failure, a heart attack, or heart surgery) in the last year.
- You have no current or past cancer (unless it was cured and you've been cancer-free for 5+ years).
- You do not have a primary immune deficiency, uncontrolled infections, or certain infections like HIV, hepatitis B or C, or active tuberculosis, EBV, CMV, or syphilis.
- You have never had CAR-T cell therapy or other gene-modified cell therapy.
- You have not received a live vaccine within the last 4 weeks.
- You do not have a history of severe allergic reaction to tacrolimus.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests whether specially-engineered immune cells (CAR-T cells) can help people with certain autoimmune diseases that haven't gotten better with standard treatments. The cells are designed to target and remove faulty B cells that are causing the immune system to attack the body.
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
This study tests a new treatment called CC312 for people with lupus, myositis, or scleroderma that hasn't gotten better with standard therapies. It aims to see if CC312 can help control the disease when other treatments have failed.
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
This study is testing an experimental medicine called PF-08154225 to see if it can help treat several autoimmune conditions, including rheumatoid arthritis, lupus, and related disorders. It might reduce disease activity or symptoms in people who have not found relief from other treatments.
Hear when a new Autoimmune Encephalitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.